Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Pipeline Review, H1 2013


#164552

48pages

Global Markets Direct

$ 2000

In Stock

 

Global Markets Directs, 'Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), complete with latest updates, and special features on late-stage and discontinued projects. 

 

It also reviews key players involved in the therapeutic development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
  • A review of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

 

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Overview 6

An Overview of Pipeline Products for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) 7

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics under Development by Companies 9

Late Stage Products 11

Comparative Analysis 11

Mid Clinical Stage Products 12

Comparative Analysis 12

Pre-Clinical Stage Products 13

Comparative Analysis 13

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Products under Development by Companies 14

Companies Involved in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Development 15

Spectrum Pharmaceuticals, Inc. 15

Altor BioScience Corporation 16

Telormedix SA 17

Viventia Biotechnologies Inc. 18

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Drug Profiles 24

apaziquone - Drug Profile 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

apaziquone - Drug Profile 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

TMX-101 - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

oportuzumab monatox - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ALT-803 - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

TD-6989 - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

TD-3633 - Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

CEL-031 - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Drug Profile Updates 38

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Dormant Products 41

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Product Development Milestones 42

Featured News & Press Releases 42

Sep 11, 2012: Cold Genesys Announces Agreement With FDA On Special Protocol Assessment Of Phase II/III Pivotal Trial Of Bladder Cancer Candidate 42

Apr 18, 2012: Celek Pharma To Present Recent Progress On Anticancer Drug, CEL-031, At NCI's Investor Forum 43

Apr 05, 2012: Spectrum Announces Results Of Apaziquone Phase III Clinical Trials 43

Apr 02, 2012: Connaught Strain Of BCG Shows Potential To Treat Non-Muscle-Invasive Bladder Cancer In Phase III Study 44

Mar 19, 2012: Telormedix’s TMX-101 Exhibits High Safety In Phase I/II Trial For Non-Muscle Invasive Bladder Cancer 45

Jan 19, 2012: OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium 45

 

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 48

Disclaimer 48


Number of Products Under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2013 7
Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Spectrum Pharmaceuticals, Inc., H1 2013 15
Altor BioScience Corporation, H1 2013 16
Telormedix SA, H1 2013 17
Viventia Biotechnologies Inc., H1 2013 18
Assessment by Monotherapy Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Drug Profile Updates 38
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics - Dormant Products 41


Number of Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), H1 2013 7
Products under Development for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23